The IBN SINA Pharmaceutical Industry PLC announcements
340 Dhaka Stock Exchange announcements for The IBN SINA Pharmaceutical Industry PLC (IBNSINA) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2022 (23).
- Alpha Credit Rating Limited (AlphaRating) has assigned surveillance rating of the Company as \"AA+\" in the long term an
Alpha Credit Rating Limited (AlphaRating) has assigned surveillance rating of the Company as \"AA+\" in the long term and \"ST-1\" in the short term along with a stable outlook based on audited financial statements of the Company as on June 30, 2022 and relevant qualitative information till December 12, 2022.
- Dividend Disbursement
The Company has informed that it has disbursed the cash dividend for the year ended June 30, 2022 to the respective shareholders.
- Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 4.63 for July-September 2022 as against Tk. 4.54 for July-September 2021. Consolidated NOCFPS was Tk. 6.75 for July-September 2022 as against Tk. 3.27 for July-September 2021. Consolidated NAV per share was Tk. 87.93 as on September 30, 2022 and Tk. 83.36 as on June 30, 2022.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 10, 2022 at 02:30 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2022.
- IBNSINA : Resumption after record date
Trading of the shares of the company will resume on 02.10.2022 after record date.
- IBNSINA : Suspension for Record date
Trading of the shares of the company will remain suspended on record date i.e., 29.09.2022.
- IBNSINA : Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 27.09.2022 to 28.09.2022 and trading of the shares will remain suspended on record date i.e., 29.09.2022.
- The Company has informed that the Board of Directors of the Company has decided to transfer a part of the Net Assets agg
The Company has informed that the Board of Directors of the Company has decided to transfer a part of the Net Assets aggregated value of BDT 20,81,69,670.00 as at June 30, 2022 of Natural Medicine Division of The IBN SINA Pharmaceutical Industry Ltd. to its Subsidiary Company, \"The IBN SINA Natural Medicine Ltd.\" for better management and to make ease of operation of its natural medicine production and businesses subject to approval by the Shareholders of (cont.1)
- (Continuation news of IBNSINA): The IBN SINA Pharmaceutical Industry Ltd. as \'Special Resolution\' in the ensuing Annua
(Continuation news of IBNSINA): The IBN SINA Pharmaceutical Industry Ltd. as \'Special Resolution\' in the ensuing Annual General Meeting of the Company scheduled to be held on October 30, 2022 and compliance with the necessary regulatory requirements in this regard. The Company has further informed that the Board has also approved the \'Vendors Agreement\' executed between The IBN SINA Pharmaceutical Industry Ltd. (Holding Company) (cont.2)
The first part of this announcement is missing from the archive. - Decision of purchasing land
The Company has informed that the Board of Directors has approved purchasing of a land measuring 27 decimals at a cost of BDT 2,30,00,000/- (two crore and thirty lac) only excluding registration and other related expenses located at Zhilanzha Mouza, Cox's Bazar Sadar, Cox's Bazar. The land will be used for constructing sales depot and training center of the company.
- Decision to transfer a part of Net Assets to its Subsidiary Company
(Continuation news of IBNSINA): and The IBN SINA Natural Medicine Ltd. (Subsidiary Company) to effect the transfer of said Net Assets at BDT 20,81,69,670.00 as at June 30, 2022 of Natural Medicine Division of The IBN SINA Pharmaceutical Industry Ltd. to its 99.99 % owned Subsidiary Company- The IBN SINA Natural Medicine Ltd. in exchange of consideration other than cash as against acquiring of Shares held by the holding Company, The IBN SINA Pharmaceutical Industry Ltd. (end)
The first part of this announcement is missing from the archive. - Dividend Declaration
The Board of Directors has recommended 60% Cash Dividend for the year ended June 30, 2022. Date of AGM: 30.10.2022, Time: 9:30 AM, Venue: Digital Platform. Record Date: 29.09.2022. The Company has also reported Consolidated EPS of Tk. 19.39, Consolidated NAV per share of Tk. 83.36 and Consolidated NOCFPS of Tk. 13.40 for the year ended June 30, 2022 as against Tk. 15.66, Tk. 68.69 and Tk. 17.67 respectively for the same period of the previous year.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (06.09.2022) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the company has informed that a meeting of the Board of Directors will be held on September 05, 2022 at 2:30 PM to consider, among others, audited financial statements of the company for the year ended June 30, 2022.
- The Company has informed that the Board of Directors has decided to demerge the Natural Medicine Division (Unit) of the
The Company has informed that the Board of Directors has decided to demerge the Natural Medicine Division (Unit) of the Company by transferring its \"Assets and Liabilities to be audited \" as at year ended June 30, 2022 in the form of \"Net Assets\" to its 99.99\% owned Subsidiary Company - The IBN SINA Natural Medicine Ltd.? - in exchange of consideration other than cash as against acquiring of the Shares held by the holding Company, (cont.)
- Decision to demerge the Natural Medicine Division
(continuation news of IBNSINA): The IBN SINA Pharmaceutical Industry Ltd. for better management and ease of operation of its natural medicine production and businesses subject to approval by the Shareholders in the next Annual General Meeting of the Company compliance with the necessary regulatory requirements in this regard. (end)
The first part of this announcement is missing from the archive. - Q3 Financials
(Q3 Un-audited): EPS was Tk. 2.76 for January-March 2022 as against Tk. 2.79 for January-March 2021; EPS was Tk. 13.26 for July 2021-March 2022 as against Tk. 10.92 for July 2020-March 2021. NOCFPS was Tk. 10.84 for July 2021-March 2022 as against Tk. 14.17 for July 2020-March 2021. NAV per share was Tk. 77.26 as on March 31, 2022 and Tk. 68.69 as on June 30, 2021.
- Board Decision to purchase of land
The Company has informed that the Board of Directors has decided to purchase a land to build central store measuring 131.49 Decimals at a cost of BDT 2,90,35,000 only excluding the cost of Registration and other related expenses located at Goalbathana Mowja, Kaliakair, Gazipur.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the company has informed that a meeting of the Board of Directors will be held on April 21, 2022 at 3:00 PM to consider, among others, un-audited financial statements of the company for the Third Quarter (Q3) period ended March 31, 2022.
- Buy Confirmation of a Corporate Sponsor Director
IBN SINA TRUST, one of the Corporate Sponsor Directors of the Company, has further reported that it has completed its buying of 50,000 shares of the Company at prevailing market price through Dhaka Stock Exchange as per declaration disseminated on 14.03.2022.
- Buy Declarations of a Corporate Sponsor Director
IBN SINA TRUST, one of the Corporate Sponsor Directors of the Company, has expressed its intention to buy 50,000 shares of the Company at prevailing market price (In the Public market) through Dhaka Stock Exchange within next 30 working days, as per Rule-4 of the BSEC (Substantial Acquisition of shares and Takeovers), Rules, 2018.
- Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. 5.97 for October-December 2021 as against Tk. 4.95 for October-December 2020; Consolidated EPS was Tk. 10.49 for July-December 2021 as against Tk. 8.19 for July-December 2020. Consolidated NOCFPS was Tk. 9.74 for July-December 2021 as against Tk. 10.48 for July-December 2020. Consolidated NAV per share was Tk. 74.49 as on December 31, 2021 and Tk. 68.69 as on June 30, 2021.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 20, 2022 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2021.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.